<DOC>
	<DOC>NCT00257192</DOC>
	<brief_summary>The purpose of this study is to determine if flexibly-dosed ziprasidone is safe and effective for the treatment of adolescents (ages 13-17) with schizophrenia</brief_summary>
	<brief_title>Safety And Efficacy Of Ziprasidone In Adolescents With Schizophrenia</brief_title>
	<detailed_description>Termination Reason: On March 24, 2009, Pfizer Inc. stopped late stage Geodon pediatric clinical trials in schizophrenia (A1281134 - placebo controlled; A1281135 - open label). As recommended by the DSMB, these studies were stopped due to lack of efficacy. No safety concerns were identified.</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<criteria>Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSMIV) criteria for schizophrenia: Current symptoms were to be present for at least 7 days before screening. At the Screening and Baseline visits, subjects must have had a Brief Psychiatric Rating Scale Anchored score ≥35 and a score of ≥4 on at least 1 of the following items: unusual thought content (i.e., delusions), hallucinations, suspiciousness, or conceptual disorganization. Age 13 17 years Imminent risk of suicide or homicide, as judged by the site investigator Any history of serious or unstable medical illness, including risk for QT prolongation</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Adolescent Subjects With Schizophrenia</keyword>
</DOC>